Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 5/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19693889 | 0.87 | GPR119 (0.51) | GPR119CYP11B2EGLN2NAMPTEIF2AK4 | |
| SCHEMBL21667711 | 0.85 | GPR119 (0.62) | GPR119 | |
| SCHEMBL25224809 | 0.84 | GPR119 (0.51) | GPR119CYP11B2EGLN2NAMPTEIF2AK4 | |
| SCHEMBL29418351 | 0.84 | GPR119 (0.51) | GPR119CYP11B2EGLN2NAMPTEIF2AK4 | |
| SCHEMBL20510344 | 0.81 | CYP2C9 (0.53) | GPR119CYP11B2EGLN2 | |
| SCHEMBL20510796 | 0.81 | GPR119 (0.48) | GPR119TMEM97 | |
| SCHEMBL17029142 | 0.81 | GPR119 (0.58) | GPR119 | |
| SCHEMBL20798095 | 0.79 | GPR119 (0.64) | GPR119CYP11B2EGLN2NAMPT | |
| SCHEMBL13156786 | 0.78 | CYP11B2 (0.54) | GPR119CYP11B2ACACBNAMPT | |
| SCHEMBL13156795 | 0.77 | CYP11B2 (0.51) | GPR119CYP11B2ACACBNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577251-B2 | Modulators of the sigma-2 receptor and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2026-03-17 | — | — | US | disclosed |
| EP-3600290-B1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20240300954-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-09-12 | — | — | US | disclosed |
| US-11820774-B2 | Modulators of the sigma-2 receptor and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820774-B2 | Modulators of the sigma-2 receptor and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-11-21 | — | — | US | disclosed |
| US-20210363145-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-11-25 | — | — | US | disclosed |
| US-10961249-B2 | Modulators of the sigma-2 receptor and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200039985-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-02-06 | — | — | US | disclosed |
| EP-3600290-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | Temple University - Of The Commonwealth System of Higher Education (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018175188-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961249-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, TMEM97, OPRM1 | GPR119 61/4885CYP11B2 236/4885ACACB 2081/4885 |
| US-20200039985-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | GPR119 25/4885CYP11B2 262/4885ACACB 1763/4885 |
| US-20210363145-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | GPR119 25/4885CYP11B2 262/4885ACACB 1763/4885 |
| US-11820774-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, TMEM97, OPRM1 | GPR119 61/4885CYP11B2 236/4885ACACB 2081/4885 |
| US-20240300954-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | GPR119 25/4885CYP11B2 262/4885ACACB 1763/4885 |
| US-12577251-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, CHRNA6, NR3C2 | GPR119 108/4885CYP11B2 239/4885ACACB 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.